Mendus
Clinical-stage company developing immunotherapies to prevent tumor recurrence.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
Description
Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-19 08:00 |
Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel a…
|
English | PDF • 114.1 KB | ||
| 2021-02-18 08:00 | Swedish | PDF • 996.1 KB | |||
| 2021-02-18 08:00 | English | PDF • 991.2 KB | |||
| 2021-02-01 17:45 |
Immunicum AB (publ) meddelar att Lotta Ferm har utsetts till ny tillförordnad f…
|
Swedish | PDF • 94.8 KB | ||
| 2021-02-01 17:45 |
Immunicum AB (publ) Announces New Interim CFO Lotta Ferm
|
English | PDF • 93.1 KB | ||
| 2021-01-26 08:00 |
Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a T…
|
English | PDF • 113.2 KB | ||
| 2021-01-26 08:00 |
Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel…
|
Swedish | PDF • 116.4 KB | ||
| 2021-01-22 14:00 |
Kommuniké från extra bolagsstämma i Immunicum AB (publ) den 22 januari 2021
|
Swedish | PDF • 105.5 KB | ||
| 2021-01-22 14:00 |
Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 Janu…
|
English | PDF • 104.4 KB | ||
| 2021-01-21 08:00 |
Immunicum AB (publ) Announces Transitions in Board of Directors
|
English | PDF • 104.7 KB | ||
| 2021-01-21 08:00 |
Immunicum AB (publ) meddelar förändringar i styrelsen
|
Swedish | PDF • 106.4 KB | ||
| 2021-01-04 18:31 | Swedish | PDF • 36.0 KB | |||
| 2020-12-31 14:00 |
Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a T…
|
English | PDF • 77.3 KB | ||
| 2020-12-31 14:00 |
Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel…
|
Swedish | PDF • 80.4 KB | ||
| 2020-12-30 20:29 | English | PDF • 34.3 KB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 56,249.40 SEK |
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 55,704.80 SEK |
| 2025-02-25 | Sven Arne Andreasson | Other | Buy | 25,000 | 198,750.00 SEK |
| 2024-04-02 | Erik Manting | Other | Other | 885,648 | 425,111.04 SEK |
| 2024-04-02 | Dharminder Chahal | Other | Other | 882,048 | 423,383.04 SEK |
| 2024-04-02 | Leopold Bertea | Other | Other | 267,858 | 128,571.84 SEK |
| 2022-10-25 | Sven Arne Andreasson | Other | Sell | 15,000 | 31,950.00 SEK |
| 2022-10-12 | Sven Arne Andreasson | Other | Sell | 10,000 | 18,800.00 SEK |
| 2022-05-20 | Erik Manting | Other | Buy | 37,059 | 86,347.47 SEK |
| 2022-05-19 | Ann-Charlotte Ferm | Other | Buy | 100,000 | 215,900.00 SEK |
Peer Companies
